IMPORTANT: The overviews are provided for informational purposes only and should not be used as a substitute for talking with your doctor. Be sure to talk with your healthcare provider for a complete discussion of these conditions as well as the benefits and risks of any treatment options.
Kōya (高野), inspired by Japan’s sacred Mount Kōya, represents resilience, growth, and discovery. Just as wisdom seekers once climbed its peaks in search of enlightenment, today’s explorers and scientists push boundaries—advancing health, science, and human potential. Every step forward brings new possibilities, reminding us that challenges are meant to be overcome. This is why all R&D projects under development bear the letter K, symbolizing the relentless pursuit of progress.
We are committed to advancing science that empowers patients and providers with best-in-class treatments for every stage of venous and lymphatic care.
Lymphedema is a chronic condition characterized by the accumulation of lymphatic fluid, leading to swelling, typically in the limbs. In the United States, it’s estimated that up to 10 million individuals are affected by lymphedema and related lymphatic diseases1. Lymphedema related hospitalization costs over $1B a year to the health system2.
Phlebolymphedema
Cancer-related lymphedema
Primary lymphedema
Lipedema with secondary lymphedema
A FDA-cleared wearable compression treatment indicated for the treatment of lymphedema, phlebolymphedema, venous insufficiency, lipedema, related conditions to chronic edema and supports mobility during treatment4.
Multiple randomized controlled studies including NILE (2022) and TEAYS (2024) showed that Dayspring provides superior outcomes in edema reduction, quality of life, and adherence compared to standard of care5,6.
Diagnosing lymphedema remains challenging due to overlapping symptoms with other conditions, lack of early detection methods, and limited access to specialized diagnostics.
TissueIQ is an innovative multi-modal analyzer designed to provide objective, real-time assessment of tissue changes beneath the skin, offering a modern approach to detecting early and progressive lymphedema-related changes, often before visible swelling occurs.
Chronic Venous Insufficiency (CVI) represents a significant and growing therapeutic need within the health care system. This condition results from venous reflux or obstruction leads to venous hypertension with consequent pain, edema, varicose veins, hyperpigmentation, and ulceration of the lower extremities.
Impacts 25 million adults in the US
the annual cost of venous ulcer care is estimated to be $3 billion
suffering from advanced disease
Impacts up to 40% of women and 17% of men in the United States
An active pipeline development program by Koya that aims to provide a minimally invasive ablation solution that is clinically effective while improving the overall patient experience and accessibility.
Deep Vein Thrombosis (DVT) is a common but often silent illness that can result insuffering and death if not recognized and treated effectively.
DVT occurs in ≈2 million Americans each year.
Treatment cost per patient can be up to $23,000 a year
Up to $10 billion cost to health system a year
K1 is an active pipeline endovascular interventional development program by Koya focused on improving overall patient access and clinical outcomes for those suffering from chronic complications from DVT.
.avif){kind=logo}
